FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980596769> ?p ?o ?g. }

• W2980596769 endingPage "A664" @default.
• W2980596769 startingPage "A664" @default.
• W2980596769 abstract "SESSION TITLE: Monday Medical Student/Resident Case Report Posters SESSION TYPE: Med Student/Res Case Rep Postr PRESENTED ON: 10/21/2019 02:30 PM - 03:15 PM INTRODUCTION: Pembrolizumab is a humanized antibody that targets the programmed cell death 1 (PD-1) receptor of lymphocytes. Pembrolizumab is a first-line, single-agent treatment of metastatic non-small cell lung cancer in patients with tumors with high PD-L1 expression (tumor proportion score ≥ 50%) [1]. Pericardial effusion is very rarely reported side effect of pembrolizumab and only reported three times in the literature. We report a loculated pericardial effusion with early tamponade physiology in a patient actively treated with pembrolizumab CASE PRESENTATION: 62 year-old man with a history of poorly-differentiated, metastatic squamous cell carcinoma of the right upper lobe (PD-1 positive), diagnosed 6 months prior to admission, presented with abnormal chest imaging (Figures 1,2,3). He was found to have a large pericardial effusion on CT Thorax. The patient had been initiated on pembrolizumab 4 months prior. The patient underwent a transthoracic echocardiogram that demonstrated a large pericardial effusion suggestive of tamponade physiology (figure 4). A pericardial window with subxiphoid approach was performed with pericardial biopsy. A total of 400ml of orange fluid was drained. The pericardial biopsy and fluid cytology showed benign chronic inflammation with microbiological workup. The patient was discharged home seven days later. Pembrolizumab was ultimately discontinued after exclusion of infectious, inflammatory or malignant etiology. Corticosteroids therapy was initiated. DISCUSSION: Immune checkpoint inhibitors have been increasingly used for treatment various malignant therapies. Reported side-effects include cases of hepatitis, colitis, pneumonitis and thyroiditis. Acute immune-related pericarditis has been reported with two other PD-1 inhibitors, nivolumab and ipilimumab. However, this case represents the fourth case of pembrolizumab associated pericardial effusion. Most cases have been reported to happen in the first 3 months of starting immunotherapy [2]. Pericardial biopsy is of paramount importance as it will decide whether the pericardial effusion is of malignant origin or an autoimmune reaction to pembrolizumab. Immune-related pericarditis is reported to respond to steroids and such cases need to monitor for recurrence of pericardial effusions CONCLUSIONS: Immune related pericarditis is an important side effect of PDL-1 inhibitors. It maybe a sign of response to immunotherapy in the correct clinical setting. Diagnosing and managing cardiac tamponade is very important in these patients. Reference #1: Garon EB, Rizvi NA, Hui R, et al; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-2028. [PubMed 25891174] Reference #2: Non-parallel anti-tumour effects of pembrolizumab: a case of cardial tamponade - Tachihara - 2019 - Respirology Case Reports - Wiley Online Library Kolla BC, and Patel MR. 2016. DISCLOSURES: No relevant relationships by Adam Austin, source=Web Response No relevant relationships by Wafic Itani, source=Web Response No relevant relationships by Lezah McCarthy, source=Web Response No relevant relationships by Kristoffer Neu, source=Web Response" @default.
• W2980596769 created "2019-10-25" @default.
• W2980596769 creator A5003704868 @default.
• W2980596769 creator A5044794410 @default.
• W2980596769 creator A5048479319 @default.
• W2980596769 creator A5053530003 @default.
• W2980596769 date "2019-10-01" @default.
• W2980596769 modified "2023-10-18" @default.
• W2980596769 title "LOCULATED PERICARDIAL EFFUSION SECONDARY TO PEMBROLIZUMAB" @default.
• W2980596769 doi "https://doi.org/10.1016/j.chest.2019.08.645" @default.
• W2980596769 hasPublicationYear "2019" @default.
• W2980596769 type Work @default.
• W2980596769 sameAs 2980596769 @default.
• W2980596769 citedByCount "1" @default.
• W2980596769 countsByYear W29805967692019 @default.
• W2980596769 crossrefType "journal-article" @default.
• W2980596769 hasAuthorship W2980596769A5003704868 @default.
• W2980596769 hasAuthorship W2980596769A5044794410 @default.
• W2980596769 hasAuthorship W2980596769A5048479319 @default.
• W2980596769 hasAuthorship W2980596769A5053530003 @default.
• W2980596769 hasBestOaLocation W29805967691 @default.
• W2980596769 hasConcept C121608353 @default.
• W2980596769 hasConcept C126322002 @default.
• W2980596769 hasConcept C126838900 @default.
• W2980596769 hasConcept C141071460 @default.
• W2980596769 hasConcept C2777573719 @default.
• W2980596769 hasConcept C2777701055 @default.
• W2980596769 hasConcept C2778607678 @default.
• W2980596769 hasConcept C2779074627 @default.
• W2980596769 hasConcept C2779634585 @default.
• W2980596769 hasConcept C2779827179 @default.
• W2980596769 hasConcept C2780057760 @default.
• W2980596769 hasConcept C2781001862 @default.
• W2980596769 hasConcept C2781175549 @default.
• W2980596769 hasConcept C71924100 @default.
• W2980596769 hasConceptScore W2980596769C121608353 @default.
• W2980596769 hasConceptScore W2980596769C126322002 @default.
• W2980596769 hasConceptScore W2980596769C126838900 @default.
• W2980596769 hasConceptScore W2980596769C141071460 @default.
• W2980596769 hasConceptScore W2980596769C2777573719 @default.
• W2980596769 hasConceptScore W2980596769C2777701055 @default.
• W2980596769 hasConceptScore W2980596769C2778607678 @default.
• W2980596769 hasConceptScore W2980596769C2779074627 @default.
• W2980596769 hasConceptScore W2980596769C2779634585 @default.
• W2980596769 hasConceptScore W2980596769C2779827179 @default.
• W2980596769 hasConceptScore W2980596769C2780057760 @default.
• W2980596769 hasConceptScore W2980596769C2781001862 @default.
• W2980596769 hasConceptScore W2980596769C2781175549 @default.
• W2980596769 hasConceptScore W2980596769C71924100 @default.
• W2980596769 hasIssue "4" @default.
• W2980596769 hasLocation W29805967691 @default.
• W2980596769 hasOpenAccess W2980596769 @default.
• W2980596769 hasPrimaryLocation W29805967691 @default.
• W2980596769 hasRelatedWork W1593454398 @default.
• W2980596769 hasRelatedWork W1969510662 @default.
• W2980596769 hasRelatedWork W2019017454 @default.
• W2980596769 hasRelatedWork W2117668233 @default.
• W2980596769 hasRelatedWork W2400307924 @default.
• W2980596769 hasRelatedWork W3133762537 @default.
• W2980596769 hasRelatedWork W3154542173 @default.
• W2980596769 hasRelatedWork W4213215996 @default.
• W2980596769 hasRelatedWork W4285798062 @default.
• W2980596769 hasRelatedWork W4312444145 @default.
• W2980596769 hasVolume "156" @default.
• W2980596769 isParatext "false" @default.
• W2980596769 isRetracted "false" @default.
• W2980596769 magId "2980596769" @default.
• W2980596769 workType "article" @default.